NIAID Continues Recruitment for 5,000-Participant Genetic Immune Disorder Study
Long-Term Observational Study Spanning 30 Years
The NIAID-led NCT00001467 is an ongoing observational study analyzing patients with inherited immune disorders and their blood relatives. Initiated in June 1995, the study aims to enroll 5,000 participants and is conducted at the NIH Clinical Center in Bethesda, Maryland. Unlike drug-interventional Phase 1, 2, or 3 trials, this study combines cross-sectional genomic analysis with long-term natural history tracking. Updated records as of May 2026 show that the protocol functions as a sustainable research infrastructure for discovering rare variants and linking genotype to phenotype.
Precision Classification of DOCK8, STAT1, GATA2, and STAT3 Deficiencies
The study includes immune deficiencies and dysregulation related to DOCK8, STAT1, GATA2, and STAT3. DNA and immune cells are analyzed from blood, oral cells, and skin tissue to identify causative variants, incomplete penetrance, and variable expressivity, as well as to detect carriers within families. A key focus is interpreting how single-gene defects lead to diverse clinical outcomes such as infections, allergies, and autoimmunity. Diagnostic results are communicated to treating physicians or genetic counselors to directly inform treatment choices and family planning.
A Platform for Refining Treatment Pathways Rather Than Drug Trials
This study does not involve test drugs or devices and does not evaluate the efficacy of specific molecular targets. Instead, molecular diagnostics are used to stratify patients and connect them to appropriate treatment pathways, including immunoglobulin replacement, infection prevention, immunosuppression, or allogeneic hematopoietic stem cell transplantation (HSCT). For DOCK8 deficiency, allogeneic HSCT is considered the only curative treatment, with an 84% survival rate among 81 patients in an international retrospective cohort. Thus, genetic diagnosis goes beyond confirming a diagnosis to becoming a clinical decision-making tool for determining transplant timing and risk assessment.
Intersection with an Already Competitive Immunoglobulin Market
Standard treatments for antibody-deficient patients include Takeda (TAK)'s HyQvia, Grifols (GRFS)'s Xembify, and CSL Limited (CSL)'s Hizentra. HyQvia combines human immunoglobulin with recombinant human hyaluronidase PH20 to replenish IgG and temporarily lower subcutaneous hyaluronan barriers; it received FDA approval for adults in September 2014 and for 2–16-year-olds in April 2023. Xembify, a subcutaneous human immunoglobulin-klhw for IgG replacement, received FDA approval in July 2019 and label expansion to include treatment-naïve patients in July 2024. The global immunoglobulin market is projected to reach USD 22.15 billion in 2025, and the genetic patient stratification from this study will serve as a foundation to distinguish between candidates for replacement therapy and those for curative transplantation or gene therapy.
From an investor perspective, this study does not generate direct drug value events but instead creates an upstream infrastructure by generating a 5,000-participant genotype-phenotype dataset to define targets and patient selection criteria for rare immune disorders. In the short term, the refinement of treatment eligibility through molecular diagnostics is critical in the USD 22.15 billion market where approved immunoglobulin products like HyQvia, Xembify, and Hizentra compete. For researchers, connecting the penetrance and natural history of DOCK8, STAT1, GATA2, and STAT3 deficiencies improves biomarker development and interventional trial design. In the medium to long term, the natural history data accumulated in this observational phase can be used for HSCT and gene therapy in defining control groups, enrollment criteria, and clinical endpoints, giving it a strong Watchlist character.
Source: ClinicalTrials.gov (api_ct)